GSK (LSE: GSK) shares recently closed at £17.50, raising the question of whether that price remains justified by the earnings the pharmaceutical group is currently generating.
Over the past five years, GSK shares have gained 51.8%, a performance that puts significant weight on whether current and future earnings can sustain that kind of valuation.
Fresh trial results for HIV therapy Cabenuva and ongoing development work on the B7H3 cancer programme have the potential to shift investor expectations for future profit growth and cash generation.
Those pipeline developments feed directly into how much investors may be willing to pay for each pound of earnings, making the pipeline narrative central to any valuation discussion.
On a price-to-earnings basis, GSK currently trades at approximately 14.5x, which sits well below the wider pharmaceuticals industry average of roughly 21.8x and even further below the peer group mark of around 46.2x.
That gap suggests investors are paying less per pound of reported profit for GSK than for the majority of comparable drug makers operating in the same space.
A fair value model blending GSK-specific factors including margins, growth assumptions, risk profile, and size points to a higher P/E than where the shares are currently trading, placing the stock in undervalued territory on that framework.
Community views on the stock remain divided, with bulls arguing that the market is not fully crediting GSK for what one narrative describes as its “stated greater than £40 billion 2031 sales outlook and the potential upside from oncology and long acting injectables.”
Bears counter that structural pressure is building, with one narrative highlighting that “the 9% decline in General Medicines sales in Q2 and the downgrade to full year guidance indicate structural pressure from aging brands and generic competition that could drag on revenue and dilute the margin uplift expected from higher priced therapies.”
Those two positions place the stock at either 19% undervalued or 20% overvalued depending on which set of assumptions an investor treats as the more credible path forward.
The bull case rests heavily on the pipeline delivering commercially meaningful results, particularly across the oncology and long-acting injectable segments that GSK has positioned as future growth drivers.
The bear case centers on a combination of declining legacy revenues and the risk that new specialty medicines cannot fully offset the margin drag from aging brands facing generic competition.
For investors comparing GSK against other opportunities on an earnings-power basis, the P/E discount relative to industry peers remains one of the more concrete data points available.
Whether that discount reflects a genuine opportunity or a well-founded market skepticism about earnings durability will likely depend on how the Cabenuva programme and broader pipeline progress over the coming reporting periods.
